Live feed
Filing
SCHEDULE 13D/A
SCHEDULE 13D/A0000929638-26-000185·CASI Pharmaceuticals, Inc.
Schedule 13D ownership disclosure
CASI PHARMACEUTICALS INC
Ordinary Shares, par value US$0.0001 per share · CUSIP: G1933S101
Event date: 2025-09-30
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- IDG-Accel China Growth Fund III L.P.Reported CIK 0001508829
Shares: 915,850 · Class: 4.5%
- IDG-Accel China III Investors L.P.Reported CIK 0001550193
Shares: 915,850 · Class: 4.5%
- IDG-Accel China Growth Fund III Associates L.P.Reported CIK 0001550192
Shares: 915,850 · Class: 4.5%
- IDG-Accel China Growth Fund GP III Associates Ltd.Reported CIK 0001564281
Shares: 915,850 · Class: 4.5%
- Ho Chi SingReported CIK 0001545806
Shares: 915,850 · Class: 4.5%
- Zhou QuanReported CIK 0001491503
Shares: 992,638 · Class: 4.8%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0000929638-26-000185
- Form type
- SCHEDULE 13D/A
- Filer
- CASI Pharmaceuticals, Inc.
- CIK
- CIK 1962738
- Filed
- Jan 20, 2026
- Reporting period
- Sep 30, 2025
- Description
- Schedule 13D beneficial ownership